BoironBOIRF 62 EV-to-FCF is 14.57 as of Jun. 28, 2026, which is 16% below its 10-year median of 17.36. GuruFocus rates BOIRF with a GF Score™ of 62/100 and a GF Value™ of $38.49 (Fairly Valued). The stock has 5 warning signs investors should review. Among 559 Drug Manufacturers companies, Boiron ranks better than 61.72% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Boiron's Enterprise Value is $501.9 Mil.
Boiron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $34.5 Mil. Therefore, Boiron's EV-to-FCF for today is 14.57.
The historical rank and industry rank for Boiron's EV-to-FCF or its related term are showing as below:
BOIRF'
s EV-to-FCF Range Over the Past 10 Years
Min: 7.92 Med: 17.36 Max: 51.65
Current: 14.87
During the past 13 years, the highest EV-to-FCF of Boiron was 51.65. The lowest was 7.92. And the median was 17.36.
BOIRF's EV-to-FCF is ranked better than 61.72% of 559
companies
in the Drug Manufacturers industry
Industry Median: 19.97
vs BOIRF: 14.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-06-28), Boiron's stock price is $31.90.
Boiron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.190. Therefore, Boiron's PE Ratio (TTM) for today is 14.57.
Boiron (OTCPK:BOIRF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Boiron's share price for today is $31.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Boiron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Boiron EV-to-FCF Related Terms
Boiron EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Boiron's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boiron EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Boiron's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Boiron's EV-to-FCF falls into.
Boiron's current Enterprise Value is $501.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Boiron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $34.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boiron (BOIRF) has a EV-to-FCF of 14.57 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Boiron and its competitors. This is 16% below median its historical median of 17.36. Over the past decade, Boiron's EV-to-FCF has ranged from 7.92 to 51.65. According to the industry distribution chart, Boiron ranks #214 out of 559 companies in the Drug Manufacturers industry, placing it in the top 38.3%.
Is Boiron's EV-to-FCF too high?
Boiron's current EV-to-FCF of 14.57 is 16% below median its 10-year median of 17.36. Over the past 10 years, this metric has ranged from a low of 7.92 to a high of 51.65. The Drug Manufacturers industry median EV-to-FCF is 19.97. Boiron's value of 14.57 is 27% below this industry median. Based on the distribution chart, Boiron ranks #214 out of 559 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Boiron has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Boiron's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Boiron ranks #214 out of 559 companies for EV-to-FCF. This puts Boiron in the upper half of its industry. The industry median EV-to-FCF is 19.97. Boiron's value of 14.57 is 27% below this benchmark. Historically, Boiron's own EV-to-FCF has ranged from 7.92 to 51.65 over the past decade. While the company's 10-year median is 17.36 vs. the industry median of 19.97, Boiron has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 19.97, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boiron's current EV-to-FCF of 14.57 is 27% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Boiron and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 19.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boiron's current EV-to-FCF is 14.57, which is 16% below median its own 10-year median of 17.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boiron stock overvalued right now?
Based on GuruFocus' analysis, Boiron (BOIRF) is currently considered Fairly Valued. The stock's GF Value™ is $38.49, compared to a current price of $31.90 — trading 17.1% below its estimated fair value. The current EV-to-FCF is 14.57, which is 16% below median its 10-year median of 17.36 and 27% below the Drug Manufacturers industry median of 19.97. Boiron's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Boiron (BOIRF), the current EV-to-FCF is 14.57 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boiron (BOIRF) Overvalued in 2026?
Based on GuruFocus' analysis, Boiron stock appears to be undervalued.
The current stock price of $31.90 is trading 17.1% below its estimated GF Value™ of $38.49.
GuruFocus considers Boiron to be Fairly Valued.
Key valuation signals for BOIRF:
EV-to-FCF: 14.57 (16% below median its 10-year median of 17.36)
GF Value™: $38.49 vs. price of $31.90 (17.1% below fair value)
Industry Position: 27% below the Drug Manufacturers median (#214 of 559)
No single metric tells the full story. See the BOIRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boiron SA is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.
62GF Score
Get the complete analysis for BOIRF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOIRF has been successfully added to your 
